Publications by authors named "A Tricerri"
Article Synopsis
- Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) primarily targets small- and medium-sized arteries, leading to conditions like rapidly progressive glomerulonephritis, particularly affecting the kidneys.
- Infections are known triggers for this autoimmune disorder, and recent studies suggest a link between SARS-CoV-2 infection and acute kidney injury (AKI).
- The text presents a specific case of a 61-year-old man who developed new-onset diffuse proliferative ANCA-associated glomerulonephritis following COVID-19.
Article Synopsis
- Choking is a serious issue causing many health problems and deaths, particularly among young children and seniors, and it often goes unreported.
- A study analyzed 138 choking incidents in a Rome hospital, with the majority of cases involving people aged 40-59, and common choking hazards including fish and meat bones.
- To prevent choking, awareness and education on risk factors are crucial, emphasizing the importance of proper chewing and handling of food.
Introduction: In this paper, we investigated whether cholecalciferol supplementation may increase the risk of stone recurrence in patients with calcium nephrolithiasis and Vitamin D deficiency.
Methods: Thirty-three stone formers (56 ± 17 years old, 12 males) with 25(OH)D < 20 ng/mL were considered. Calcium excretion and urine supersaturation with calcium oxalate (ßCaOx) and brushite (ßbsh) were evaluated, both before and after cholecalciferol supplementation.
Introduction: In this paper we investigated whether cholecalciferol supplementation, prescribed to treat vitamin D deficiency in patients with nephrolithiasis, increased the risk of stone recurrence.
Methods: Calcium excretion and urine supersaturation with calcium oxalate (βCaOx) and brushite (βbsh) were evaluated in 33 kidney stone formers (aged 56±17; 12 males), both before and after therapy with cholecalciferol, prescribed as oral bolus of 100.000-200.
Primary hyperparathyroidism (PHPT) may favor nephrolithiasis mainly through an increase in calcium and phosphate urinary excretion. Cinacalcet exhibits good efficacy to control hypercalcemia in PHPT, but it is not so far known whether it might be a useful tool to prevent stone recurrences. Of 67 patients with PHPT and recurrent nephrolithiasis, 55 underwent parathyroidectomy (PTX) and 12, not eligible to PTX, were prescribed Cinacalcet.
View Article and Find Full Text PDF